Rusan Pharma launches R&D centre, special manufacturing unit in Gujarat

Rusan Pharma today launched a Rs 100 crore-R&D centre and specialized manufacturing unit for transdermal patches at Kandla Special Economic Zone (SEZ) in Gujarat.

Founded in 1994, the company is engaged in de-addiction and pain management products in the domestic and internationalmarkets.

“We are setting up a R&D centre ‘Navin Saxena Research and Technology’ (NSRT), in association with Clinical research organisation – ‘Quest Care’ and a specialised manufacturing unit for transdermal patches at the Kandla SEZ,” Rusan Pharma Chairman Navin Saxena told PTI after inaugurating the centre here.

“We are investing around Rs 200 crore in NSRT and QuestCare in the two phase programme by 2017, of which Rs 100 crore (are) already invested in phase I. It will be funded through internal accruals and bank loans.

“Through this new facilities, India can enter the innovation drive for the niche categories targeted by NSRT as a participation of USD 375 million global licensing market,” he added.

Research at NSRT will focus on pain, addiction, central nervous system and orphan diseases, drug delivery and platform technologies and it also aims to undertake contract research and joint development projects.

QuestCare is a company’s ultra modern bio-equivalence clinical research organisation, which was set up as JV withChennai based Quest Life Sciences, he said.

The company also proposes to invest in further innovation for new targeted delivery drugs for breast cancer, naltrexone implant for alcohol abuse, dengue and Zica viruses.

Rusan Group companies together have a current turnover of Rs 300 crore and intend to grow to 600 crore in 2018, Saxena said.

It has also announced the agreement with Brazil Health Ministry for their program for smoking cessation.

“With our efforts and innovation, we announce the biggest government and private Indian company deal between Brazil Health Ministry & Rusan Pharma for USD 20 million per annum. The company’s ‘2baconil’ drug will be used for the Brazilian government’s program for smoking cessation,” Saxena said.


Source: ETHealthworld

Date: 4th April, 2016.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s